AbbVie Launches Aquipta: A New Oral Treatment for Migraine Prevention

AbbVie, a global biopharmaceutical leader, has officially launched Aquipta (generic name: Atogepant) in Japan, marking a significant advancement in the prevention of migraine attacks for adults. Approved for market sale as of April 17, 2026, Aquipta represents a new chapter in migraine management, aimed at alleviating the burden of this debilitating condition that affects millions of individuals worldwide.

The Science Behind Aquipta

Aquipta is classified as a CGRP receptor antagonist, specifically designed to reduce the frequency of migraine episodes. By targeting the Calcitonin Gene-Related Peptide (CGRP), a molecule closely linked to the onset of migraines, Aquipta works effectively when taken once daily. Research indicates that CGRP levels rise during migraine attacks, and by inhibiting this peptide, Aquipta can potentially decrease the intensity and frequency of these episodes, offering much-needed relief for patients.

This medication has gained approval in over 60 countries, showcasing its global acceptance and efficacy in preventing migraines. It is marketed under different names as well, such as AQUIPTA in the EU and QULIPTA in the US, Canada, and Israel. The broad regulatory approval underscores the trust in its capabilities to address migraine prevention.

Understanding the Impact of Migraines

Migraine is a widespread condition affecting approximately 14% of the global population, with a notable prevalence among women. In Japan, the migraine prevalence stands at 8.4% for individuals aged 15 and over. The condition is characterized by severe, pulsating headaches on one side of the head, often accompanied by nausea, vomiting, and sensitivity to light and sound. These symptoms can significantly interfere with daily activities and contribute to reduced productivity, particularly in the workplace.

A significant concern is that migraines are not just a medical issue but also a substantial socio-economic challenge. The European studies suggest that migraines could account for 1.2% to 2% of GDP loss, showcasing the economic ramifications of this condition. Women, in particular, face higher losses in productivity due to unremunerated labor associated with migraine-related disruptions.

AbbVie’s Commitment to Migraine Management

AbbVie is dedicated to advancing the treatment options available to migraine sufferers. The organization continually invests in research that aims to enhance the understanding and management of migraine treatments. Through collaborations with healthcare professionals, AbbVie strives to understand the diverse needs of migraine patients more comprehensively.

A New Era for Migraine Sufferers

The introduction of Aquipta is a game-changer for many adults who suffer from migraines, as it provides a new choice among preventive medications—a critical need in the treatment landscape. Prior guidelines suggest that individuals experiencing two or more severe migraine attacks per month should consider preventive therapies, and Aquipta's addition to the market may encourage more patients to seek help.

Product Overview

- Product Name: Aquipta Tablets 10mg, 30mg, 60mg
- Generic Name: Atogepant Hydrate
- Indication: Prevention of migraine episodes
- Dosage: Typically, adult patients should take 60mg orally once daily.
- Approval Date: February 19, 2026
- Launch Date: April 17, 2026
- Manufacturing Company: AbbVie Inc.

Conclusion

The launch of Aquipta is a remarkable step forward in migraine prevention, promising relief for countless individuals. As more patients gain access to comprehensive treatment options, the hope is that their quality of life will significantly improve. With ongoing commitment from AbbVie to advancing migraine treatment, the future looks promising for those struggling with this challenging condition.